JP7554041B2 - Limb Slimming Agent - Google Patents
Limb Slimming Agent Download PDFInfo
- Publication number
- JP7554041B2 JP7554041B2 JP2019107417A JP2019107417A JP7554041B2 JP 7554041 B2 JP7554041 B2 JP 7554041B2 JP 2019107417 A JP2019107417 A JP 2019107417A JP 2019107417 A JP2019107417 A JP 2019107417A JP 7554041 B2 JP7554041 B2 JP 7554041B2
- Authority
- JP
- Japan
- Prior art keywords
- weight
- limb
- parts
- slimming
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000003414 extremity Anatomy 0.000 claims description 74
- 239000003795 chemical substances by application Substances 0.000 claims description 52
- 239000000284 extract Substances 0.000 claims description 46
- 239000009520 bofu-tsusho-san Substances 0.000 claims description 40
- 244000309466 calf Species 0.000 claims description 22
- 210000000689 upper leg Anatomy 0.000 claims description 22
- 230000037237 body shape Effects 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 description 23
- 210000000577 adipose tissue Anatomy 0.000 description 17
- 241000207929 Scutellaria Species 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 239000000654 additive Substances 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 210000003205 muscle Anatomy 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 230000001603 reducing effect Effects 0.000 description 9
- 238000000034 method Methods 0.000 description 8
- 235000006886 Zingiber officinale Nutrition 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 235000008397 ginger Nutrition 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 230000000144 pharmacologic effect Effects 0.000 description 7
- 239000003925 fat Substances 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 235000012054 meals Nutrition 0.000 description 5
- 208000008589 Obesity Diseases 0.000 description 4
- 241000234314 Zingiber Species 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 210000001596 intra-abdominal fat Anatomy 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 235000020824 obesity Nutrition 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 229940056729 sodium sulfate anhydrous Drugs 0.000 description 4
- 241000219475 Bougainvillea Species 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- 241000212948 Cnidium Species 0.000 description 3
- 241000218671 Ephedra Species 0.000 description 3
- 241000555712 Forsythia Species 0.000 description 3
- 244000303040 Glycyrrhiza glabra Species 0.000 description 3
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 3
- 235000017443 Hedysarum boreale Nutrition 0.000 description 3
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 3
- 235000006751 Platycodon Nutrition 0.000 description 3
- 244000274050 Platycodon grandiflorum Species 0.000 description 3
- 244000299790 Rheum rhabarbarum Species 0.000 description 3
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 244000273928 Zingiber officinale Species 0.000 description 3
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 229950008138 carmellose Drugs 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 235000012041 food component Nutrition 0.000 description 3
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000000053 physical method Methods 0.000 description 3
- 229930189914 platycodon Natural products 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241000544270 Angelica acutiloba Species 0.000 description 2
- 241000132012 Atractylodes Species 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- HFCSXCKLARAMIQ-UHFFFAOYSA-L disodium;sulfate;hydrate Chemical compound O.[Na+].[Na+].[O-]S([O-])(=O)=O HFCSXCKLARAMIQ-UHFFFAOYSA-L 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000010440 gypsum Substances 0.000 description 2
- 229910052602 gypsum Inorganic materials 0.000 description 2
- 239000012676 herbal extract Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 240000007124 Brassica oleracea Species 0.000 description 1
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 1
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 1
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 1
- 241000208328 Catharanthus Species 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 244000111489 Gardenia augusta Species 0.000 description 1
- 241000212941 Glehnia Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 235000002710 Ilex cornuta Nutrition 0.000 description 1
- 241001310146 Ilex cornuta Species 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 240000007707 Mentha arvensis Species 0.000 description 1
- 235000018978 Mentha arvensis Nutrition 0.000 description 1
- 235000016278 Mentha canadensis Nutrition 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 235000010326 Osmanthus heterophyllus Nutrition 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- 235000001630 Pyrus pyrifolia var culta Nutrition 0.000 description 1
- 244000079529 Pyrus serotina Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 235000021403 cultural food Nutrition 0.000 description 1
- 150000004691 decahydrates Chemical class 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- JAUGGEIKQIHSMF-UHFFFAOYSA-N dialuminum;dimagnesium;dioxido(oxo)silane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O JAUGGEIKQIHSMF-UHFFFAOYSA-N 0.000 description 1
- GDVKFRBCXAPAQJ-UHFFFAOYSA-A dialuminum;hexamagnesium;carbonate;hexadecahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-]C([O-])=O GDVKFRBCXAPAQJ-UHFFFAOYSA-A 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000020805 dietary restrictions Nutrition 0.000 description 1
- 235000001916 dieting Nutrition 0.000 description 1
- 230000037228 dieting effect Effects 0.000 description 1
- 229940124568 digestive agent Drugs 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 229940066493 expectorants Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- -1 flavorings Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229940068517 fruit extracts Drugs 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229960001545 hydrotalcite Drugs 0.000 description 1
- 229910001701 hydrotalcite Inorganic materials 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 230000002366 lipolytic effect Effects 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- ZADYMNAVLSWLEQ-UHFFFAOYSA-N magnesium;oxygen(2-);silicon(4+) Chemical compound [O-2].[O-2].[O-2].[Mg+2].[Si+4] ZADYMNAVLSWLEQ-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 231100000272 reduced body weight Toxicity 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
本発明は、本来的に痩せにくい、右上腕、左上腕、右太股、左太股、右脹脛、及び左脹脛の少なくともいずれかの周径を低減できる四肢スリミング剤に関する。 The present invention relates to an extremity slimming agent that can reduce the circumference of at least one of the upper right arm, upper left arm, right thigh, left thigh, right calf, and left calf, which are inherently difficult to slim down.
近年、食文化の欧米化に伴い、日本人の脂質摂取量は増加しており、過剰に摂取された脂質は脂肪の形で体内に蓄積され、肥満等の原因となっている。肥満は脂肪組織に脂肪が過剰に蓄積した状態であり、様々な健康障害を合併することが知られている。特に、肥満において認められる内臓脂肪の蓄積は、メタボリックシンドロームを経て、糖尿病、脂質異常症、高血圧等の生活習慣病を引き起こし、さらに動脈硬化を進展させることで、心筋梗塞、脳卒中等の重篤疾患をも発症し得る。このため、体内に蓄積した脂肪を低減させることは重要課題として認識されている。 In recent years, as food culture has become more Westernized, the amount of lipid intake by Japanese people has increased, and excess lipid intake accumulates in the body in the form of fat, causing obesity and other conditions. Obesity is a state in which fat accumulates excessively in adipose tissue, and is known to be accompanied by various health disorders. In particular, the accumulation of visceral fat seen in obesity can lead to lifestyle-related diseases such as diabetes, dyslipidemia, and hypertension through metabolic syndrome, and can further progress to arteriosclerosis, leading to serious diseases such as myocardial infarction and stroke. For this reason, reducing the amount of fat accumulated in the body is recognized as an important issue.
近年、肥満に対する体脂肪の低減を目的として様々な経口剤が報告されている。このような経口剤の服用は、運動を要さず手軽であり継続が容易である点で広く支持されている。体脂肪低減剤としては、例えば、脂肪の蓄積を抑制し、蓄積した脂肪を分解することで内臓脂肪を低減するラクトフェリン(特許文献1)、体脂肪の燃焼の促進作用を有する茶抽出物(特許文献2)、抗肥満効果及び脂肪分解活性を有する柑橘類果実抽出物(特許文献3)等が報告されている。 In recent years, various oral agents have been reported for the purpose of reducing body fat in response to obesity. Taking such oral agents is widely supported because it does not require exercise, is easy, and is easy to continue. Examples of body fat reducing agents that have been reported include lactoferrin (Patent Document 1), which suppresses fat accumulation and reduces visceral fat by breaking down accumulated fat, tea extracts that promote the burning of body fat (Patent Document 2), and citrus fruit extracts that have anti-obesity effects and lipolytic activity (Patent Document 3).
しかしながら、運動を行わずに体脂肪を低減させる場合、体幹部分であるウエストやヒップについては体脂肪低減の効果が得られやすい一方で、四肢については冷えやすく、相対的に代謝が悪いため、体脂肪低減の効果は期待できないというのが一般常識である。従って、四肢のスリミングを希望する人は、体脂肪の低減を目的とした従来の経口剤を服用するのではなく、四肢を使った運動によってスリミングを行っているのが現状である。 However, when reducing body fat without exercise, it is common knowledge that while it is easy to achieve a reduction in body fat in the waist and hips, which are the trunk of the body, the limbs are prone to getting cold and have a relatively poor metabolism, so no effect can be expected in reducing body fat. Therefore, people who wish to slim down their limbs currently do so by exercising their limbs, rather than taking conventional oral medications aimed at reducing body fat.
本発明の目的は、四肢のスリミングが可能な剤を提供することを目的とする。 The object of the present invention is to provide an agent capable of slimming the limbs.
本発明者らが鋭意検討を行ったところ、防風通聖散が、本来的に痩せにくい四肢を効果的にスリミングできることを新たに発見した。本発明は、かかる知見に基づいて、更に検討を重ねることにより完成したものである。 After extensive research, the inventors discovered that Bofutsushosan can effectively slim down the extremities, which are difficult to slim down by nature. The present invention was completed based on this knowledge and further research.
即ち、本発明は、下記に掲げる態様の発明を提供する。
項1. 防風通聖散エキスを含有し、右上腕、左上腕、右太股、左太股、右脹脛、及び左脹脛の少なくともいずれかの周径を低減するために用いられる、四肢スリミング剤。
項2. 体形改善剤である、項1に記載の四肢スリミング剤。
項3. 更に、ウエスト及び/又はヒップの周径を低減するために用いられる、項1又は2に記載の四肢スリミング剤。
項4. 項1~3のいずれかに記載の四肢スリミング剤による四肢スリミング効果を示すプレゼンテーション方法であって、人体像またはヒト形シルエット像を用いて、上腕、左上腕、右太股、左太股、右脹脛、及び左脹脛の少なくともいずれかの太さが低減する様子を経時的に示すことを含む、方法。
That is, the present invention provides the following aspects.
Item 1. A limb slimming agent containing bofu-tsusho-san extract and used for reducing the circumference of at least one of the right upper arm, the left upper arm, the right thigh, the left thigh, the right calf, and the left calf.
Item 2. The limb slimming agent according to Item 1, which is a body shape improving agent.
Item 3. The limb slimming agent according to Item 1 or 2, which is further used to reduce waist and/or hip circumference.
Item 4. A presentation method for demonstrating the limb slimming effect of the limb slimming agent according to any one of Items 1 to 3, comprising using a human body image or a human silhouette image to show the reduction in thickness of at least one of the upper arm, left upper arm, right thigh, left thigh, right calf, and left calf over time.
本発明の四肢のスリミング剤によれば、四肢を効果的にスリミングさせることができる。また、本発明のスリミング時剤によって本来的に痩せにくい四肢をスリミングすることで、体形の改善を図ることができる。 The limb slimming agent of the present invention can effectively slim the limbs. In addition, by using the slimming agent of the present invention to slim the limbs, which are inherently difficult to slim down, it is possible to improve the body shape.
1.四肢スリミング剤
本発明の四肢スリミング剤は、防風通聖散エキスを含有することを特徴とする。以下、本発明の四肢スリミング剤について詳述する。
1. Limb Slimming Agent The limb slimming agent of the present invention is characterized by containing Bofu-tsusho-san extract. The limb slimming agent of the present invention will be described in detail below.
防風通聖散エキス
本発明の四肢スリミング剤において、防風通聖散エキスは、本来的に痩せにくい四肢、つまり、右上腕、左上腕、右太股、左太股、右脹脛、及び左脹脛の少なくともいずれかの周径を低減できる。本発明における防風通聖散は筋肉量の低下を抑制することもできるため、四肢の体脂肪を低減することによってスリミングすることができる。
In the limb slimming agent of the present invention, the bofutsushosan extract can reduce the circumference of at least one of the limbs that are inherently difficult to slim down, that is, the right upper arm, the left upper arm, the right thigh, the left thigh, the right calf, and the left calf. The bofutsushosan extract of the present invention can also suppress the decrease in muscle mass, so that the body fat of the limbs can be reduced to achieve slimming.
防風通聖散を構成する生薬は、「一般用漢方処方の手引き」(厚生省薬務局監修、日薬連漢方専門委員会編集、薬業時報社発行)によれば、トウキ、シャクヤク、センキュウ、サンシシ、レンギョウ、ハッカ、ショウキョウ、ケイガイ、ボウフウ、マオウ、ダイオウ、ボウショウ、ビャクジュツ、キキョウ、オウゴン、カンゾウ、セッコウ、及びカッセキである。書簡によっては、前記生薬の内、ビャクジュツを含まないもの(例えば「経験漢方処方分量集」、大塚敬節・矢数道明監集、医道の日本社発行)や、オウゴンを含まないもの(例えば「続漢方あれこれ」大阪読売新聞社編、浪速社発行)がある。本発明で使用される防風通聖散エキスは、これらのいずれの防風通聖散から得られるものであってもよい。 According to the "Guide to General Kampo Prescriptions" (supervised by the Pharmaceutical Affairs Bureau of the Ministry of Health and Welfare, edited by the Kampo Specialist Committee of the Japan Pharmaceutical Manufacturers Association, and published by Yakugyo Jihosha), the herbal medicines that make up Bofutsushosan are Angelica Root, Peony Root, Cnidium Root, Sanshishi, Forsythia Root, Mint, Ginger Root, Cabbage Root, Bougainvillea Root, Ephedra Root, Rhubarb, Byakujutsu, Platycodon Root, Scutellaria Root, Licorice Root, Scutellaria Root, and Catharanthus Radix. Some letters do not include Byakujutsu (for example, "Experience Kampo Prescription Quantities Collection," supervised by Otsuka Keisetsu and Yakazu Domyo, published by Ido no Nihonsha), and some do not include Scutellaria Root (for example, "Zoku Kampo Arekore," compiled by Osaka Yomiuri Shimbun, published by Naniwasha). The Bofutsushosan extract used in the present invention may be obtained from any of these Bofutsushosan.
また、防風通聖散を構成する各生薬の分量は、「一般用漢方処方の手引き」(厚生省薬務局監修、日薬連漢方専門委員会編集、薬業時報社発行)、「第十七改正日本薬局方」等によれば、トウキ1.2重量部、シャクヤク1.2重量部、センキュウ1.2重量部、サンシシ1.2重量部、レンギョウ1.2重量部、ハッカ1.2重量部、ショウキョウ0.3~1.2重量部、ケイガイ1.2重量部、ボウフウ1.2重量部またはハマボウフウ1.2重量部、マオウ1.2重量部、ダイオウ1.5重量部、ボウショウ(硫酸ナトリウム無水物換算量)0.6~1.5重量部、ビャクジュツ2重量部、キキョウ2重量部、オウゴン2重量部、カンゾウ2重量部、セッコウ2~3重量部、及びカッセキ3~5重量部である。また、書簡によっては、前記分量中、1.2重量部を全て1.5重量部としているものもある(例えば「明解漢方処方」、西岡一夫、高橋真太郎共著、浪速社発行)。 According to the "Guide to General Kampo Prescriptions" (supervised by the Ministry of Health, Labor and Welfare's Pharmaceutical Affairs Bureau, edited by the Kampo Specialist Committee of the Japan Pharmaceutical Manufacturers Association, and published by Yakugyo Jihosha) and the "17th Revised Japanese Pharmacopoeia," the amounts of each herb that makes up Bofutsushosan are as follows: Angelica acutiloba 1.2 parts by weight, Peony root 1.2 parts by weight, Cnidium rhizome 1.2 parts by weight, Gardenia japonica 1.2 parts by weight, Forsythia serrata 1.2 parts by weight, Mentha arvensis 1.2 parts by weight, and Ginger 0.3 to 1.5 parts by weight. 1.2 parts by weight, 1.2 parts by weight of Chinese holly, 1.2 parts by weight of Bougainvillea or 1.2 parts by weight of Glehnia gracilis, 1.2 parts by weight of Ephedra, 1.5 parts by weight of Rhubarb, 0.6 to 1.5 parts by weight of Bougainvillea (calculated as anhydrous sodium sulfate), 2 parts by weight of Atractylodes Root, 2 parts by weight of Platycodon Root, 2 parts by weight of Scutellaria Root, 2 parts by weight of Licorice Root, 2 to 3 parts by weight of Gypsum, and 3 to 5 parts by weight of Kasseki. Some letters also state that all of the 1.2 parts by weight in the above amounts are 1.5 parts by weight (for example, "Meikai Kampo Prescriptions," co-authored by Nishioka Kazuo and Takahashi Shintaro, published by Naniwasha).
防風通聖散エキスの製造に供される生薬調合物における各生薬の分量については、特に制限されず、前記で例示した書簡に示されている各生薬の分量で使用してもよいが、好適な例として、トウキ1.2重量部、シャクヤク1.2重量部、センキュウ1.2重量部、サンシシ1.2重量部、レンギョウ1.2重量部、ハッカ1.2重量部、ケイガイ1.2重量部、ボウフウ1.2重量部、マオウ1.2重量部、ダイオウ1.5重量部、ボウショウ(硫酸ナトリウム無水物換算量)0.6~1.5重量部、ビャクジュツ2重量部、キキョウ2重量部、オウゴン2重量部、カンゾウ2重量部、セッコウ2~3重量部(好ましくは2重量部)、及びカッセキ3~5重量部(好ましくは3重量部)であり、且つショウキョウが0.3~1.5重量部、好ましくは0.3~1.2重量部、更に好ましくは0.3~0.4重量部、特に好ましくは0.3重量部であるものが挙げられる。防風通聖散エキスの製造に供される生薬調合物におけるショウキョウの分量を上記の範囲に調節することによって、四肢スリミング効果をより好ましく向上させることができる。 There are no particular restrictions on the amount of each herb in the herb preparation used to manufacture the Bofu-tsushosan extract, and the amount of each herb shown in the letter exemplified above may be used. Suitable examples include 1.2 parts by weight of Angelica acutiloba, 1.2 parts by weight of Peony Root, 1.2 parts by weight of Cnidium Root, 1.2 parts by weight of Sanshi Fruit, 1.2 parts by weight of Forsythia Fruit, 1.2 parts by weight of Mentha Root, 1.2 parts by weight of Japanese Pear, 1.2 parts by weight of Japanese Scutellaria, 1.2 parts by weight of Japanese Scutellaria, 1.2 parts by weight of Japanese Scutellaria, 1.2 parts by weight of Japanese Scutellaria, 1.2 parts by weight of Japanese Scutellaria, 1.2 parts by weight of Japanese Scutellaria, 1.2 parts by weight of Japanese Ephedra, 1.5 parts by weight of Rhubarb, 1.2 parts by weight of Japanese Scutellaria ... Examples include 0.6 to 1.5 parts by weight of Angelica Root (converted into anhydrous sodium sulfate), 2 parts by weight of Atractylodes Root, 2 parts by weight of Platycodon Root, 2 parts by weight of Scutellaria Root, 2 parts by weight of Licorice Root, 2 to 3 parts by weight (preferably 2 parts by weight) of Gypsum, and 3 to 5 parts by weight (preferably 3 parts by weight) of Ginger, with 0.3 to 1.5 parts by weight, preferably 0.3 to 1.2 parts by weight, more preferably 0.3 to 0.4 parts by weight, and particularly preferably 0.3 parts by weight. By adjusting the amount of Ginger in the herbal preparation used to produce the Bofu-tsushosan extract to fall within the above range, the limb slimming effect can be more favorably improved.
また、ボウショウの分量は、硫酸ナトリウム無水物換算で、好ましくは0.6~1重量部、更に好ましくは0.6~0.75重量部、特に好ましくは0.7重量部を充足することによって、錠剤として成形された場合に、錠剤の硬度及び崩壊性を向上させることができる。 In addition, by using an amount of sodium sulfate anhydrous equivalent of preferably 0.6 to 1 part by weight, more preferably 0.6 to 0.75 parts by weight, and particularly preferably 0.7 part by weight, the hardness and disintegration properties of the tablet can be improved when the tablet is formed.
なお、本発明において、「防風通聖散エキスの製造に供される生薬調合物」とは、防風通聖散エキスの製造において、抽出に供される原料調合物、即ち、防風通聖散を構成する所定量の生薬を含む調合物である。また、ボウショウの硫酸ナトリウム無水物換算とは、ボウショウとして硫酸ナトリウムの水和物を使用する場合には、当該水和物を無水物重量に換算することを指す。なお、ボウショウとしては、硫酸ナトリウムの水和物(例えば、10水和物)及び/又は硫酸ナトリウム無水物が使用され、錠剤として成形された場合において錠剤の硬度及び崩壊性を向上させる観点からは、硫酸ナトリウム無水物が好ましく使用される。 In the present invention, the term "herb preparation used in the production of Bofutsushosan extract" refers to a raw material preparation used for extraction in the production of Bofutsushosan extract, i.e., a preparation containing a predetermined amount of herbs that constitute Bofutsushosan. In addition, the term "sodium sulfate anhydrous equivalent of Bofutsushosan" refers to the conversion of the hydrate to the anhydrous weight when sodium sulfate hydrate is used as Bofutsushosan. In addition, sodium sulfate hydrate (e.g., decahydrate) and/or sodium sulfate anhydrous is used as Bofutsushosan, and sodium sulfate anhydrous is preferably used from the viewpoint of improving the hardness and disintegrability of the tablet when it is formed into a tablet.
本発明で使用される防風通聖散エキスの製造に供される生薬調合物の好適な例として、当該生薬調合物の全量100重量部当たり、ショウキョウが1~5重量部、より好ましくは1~4重量部、更に好ましくは1~3重量部、特に好ましくは1~2重量部含まれているものが挙げられる。このようにショウキョウの比率が低い生薬調合物から防風通聖散エキスを得ることによって、内臓脂肪細胞分解効果をより好ましく向上させることが可能になる。このようにショウキョウの比率が高い生薬調合物から防風通聖散エキスを得ることによって、四肢スリミング効果をより好ましく向上させることが可能になる。 A suitable example of a herbal preparation used in the manufacture of the bofutsushosan extract used in the present invention is one containing 1 to 5 parts by weight, more preferably 1 to 4 parts by weight, even more preferably 1 to 3 parts by weight, and particularly preferably 1 to 2 parts by weight, of ginger per 100 parts by weight of the total amount of the herbal preparation. By obtaining the bofutsushosan extract from a herbal preparation with a low ratio of ginger in this way, it is possible to more preferably improve the visceral fat cell decomposition effect. By obtaining the bofutsushosan extract from a herbal preparation with a high ratio of ginger in this way, it is possible to more preferably improve the limb slimming effect.
また、本発明で使用される防風通聖散エキスの製造に供される生薬調合物の好適な例として、当該生薬調合物の全量100重量部当たり、ボウショウが硫酸ナトリウム無水物換算で2~6重量部、好ましくは2~4重量部、更に好ましくは2~3重量部、特に好ましくは2~2.5重量部含まれているものが挙げられる。用量及び製剤形態等にもよるが、このような比率で生薬調合物中にボウショウが含まれることによって、錠剤として成形された場合において、錠剤の硬度及び崩壊性を向上させることが可能になる。 A suitable example of a herbal preparation used in the manufacture of the Bofutsushosan extract used in the present invention is one containing 2 to 6 parts by weight, preferably 2 to 4 parts by weight, more preferably 2 to 3 parts by weight, and particularly preferably 2 to 2.5 parts by weight of Boshou, calculated as anhydrous sodium sulfate, per 100 parts by weight of the total amount of the herbal preparation. Although it depends on the dosage and formulation form, the inclusion of Boshou in the herbal preparation in such a ratio makes it possible to improve the hardness and disintegration properties of the tablet when it is formed into a tablet.
本発明で使用される防風通聖散エキスは、前記生薬調合物を公知の手法で抽出することによって得ることができる。前記生薬調合物を抽出する方法については、従来の防風通聖散エキスの抽出法と同様の方法で行えばよく、例えば、前記生薬調合物に対して、約10~20倍量の水を加え、80~100℃程度で1~3時間程度撹拌して抽出する方法が挙げられる。抽出後に、遠心分離、濾過等の固液分離に供して固形分を除去し、必要に応じて、濃縮処理や乾燥処理に供することによって防風通聖散エキスが得られる。 The bofutsushosan extract used in the present invention can be obtained by extracting the herbal preparation by a known method. The method for extracting the herbal preparation may be the same as the conventional method for extracting bofutsushosan extract, for example, by adding about 10 to 20 times the amount of water to the herbal preparation and stirring at about 80 to 100°C for about 1 to 3 hours. After extraction, the solids are removed by solid-liquid separation such as centrifugation and filtration, and if necessary, the bofutsushosan extract is obtained by subjecting it to concentration or drying treatment.
防風通聖散エキスをエキス末として得るには、固形分を除去した抽出液を、必要に応じて濃縮した後に、スプレードライ、減圧濃縮乾燥、凍結乾燥等の乾燥処理に供すればよい。また、乾燥処理(特に、スプレードライによる乾燥処理)に供する際に、必要に応じて抽出液に、デキストリン等の賦形剤を添加してもよい。このように賦形剤を添加することにより、乾燥時間を短縮することが可能になる。添加される賦形剤の種類や添加量については、一般的な漢方エキス末を製造する場合と同様である。 To obtain Bofutsushosan extract as an extract powder, the extract liquid from which the solids have been removed may be concentrated as necessary, and then subjected to a drying process such as spray drying, vacuum concentration drying, or freeze drying. In addition, when subjected to a drying process (particularly drying by spray drying), an excipient such as dextrin may be added to the extract liquid as necessary. Adding an excipient in this way makes it possible to shorten the drying time. The type and amount of excipient added are the same as when producing general herbal extract powders.
また、防風通聖散エキスを軟エキスとして得るには、形分を除去した抽出液を、減圧濃縮等によって濃縮すればよい。また、軟エキスに、適当な吸着剤(例えば無水ケイ酸、デンプン等)を加えて吸着末としてもよい。 To obtain Bofutsushosan extract as a soft extract, the extract from which the solid components have been removed may be concentrated by vacuum concentration or the like. A suitable adsorbent (e.g., silicic anhydride, starch, etc.) may also be added to the soft extract to produce an adsorbed powder.
本発明で使用される防風通聖散エキスは、エキス末又は軟エキスのいずれであってもよく、本発明の四肢スリミング剤の形態に応じて、エキス末又は軟エキスを適宜選択すればよい。また、錠剤として成形される場合においては、硬度及び崩壊性に優れた錠剤を得る観点から、エキス末であることが好ましい。 The bofutsushosan extract used in the present invention may be either an extract powder or a soft extract, and either extract powder or soft extract may be appropriately selected depending on the form of the limb slimming agent of the present invention. In addition, when formed into tablets, it is preferable to use an extract powder from the viewpoint of obtaining tablets with excellent hardness and disintegration properties.
その他の成分
本発明の四肢スリミング剤は、防風通聖散エキス単独からなるものであってもよく、製剤形態に応じた添加剤や基剤を含んでいてもよい。このような添加剤及び基剤としては、薬学的に許容されることを限度として特に制限されないが、例えば、賦形剤、結合剤、崩壊剤、滑沢剤、等張化剤、可塑剤、分散剤、乳化剤、溶解補助剤、湿潤化剤、安定化剤、懸濁化剤、粘着剤、コーティング剤、光沢化剤、水、油脂類、ロウ類、炭化水素類、脂肪酸類、高級アルコール類、エステル類、水溶性高分子、界面活性剤、金属石鹸、低級アルコール類、多価アルコール、pH調整剤、緩衝剤、酸化防止剤、紫外線防止剤、防腐剤、矯味剤、香料、粉体、増粘剤、色素、キレート剤等が挙げられる。これらの添加剤は、1種単独で使用してもよく、また2種以上を組み合わせて使用してもよい。また、これらの添加剤及び基剤の含有量については、使用する添加剤及び基剤の種類、筋肉量低下抑制剤の製剤形態等に応じて適宜設定される。
Other components The limb slimming agent of the present invention may be composed of Bofutsushosan extract alone, or may contain additives and bases according to the formulation. Such additives and bases are not particularly limited as long as they are pharmacologic acceptable, and examples thereof include excipients, binders, disintegrants, lubricants, isotonicity agents, plasticizers, dispersants, emulsifiers, solubilizers, wetting agents, stabilizers, suspending agents, adhesives, coating agents, glossing agents, water, oils and fats, waxes, hydrocarbons, fatty acids, higher alcohols, esters, water-soluble polymers, surfactants, metal soaps, lower alcohols, polyhydric alcohols, pH adjusters, buffers, antioxidants, UV inhibitors, preservatives, flavorings, fragrances, powders, thickeners, pigments, chelating agents, etc. These additives may be used alone or in combination of two or more. The content of these additives and bases is appropriately set according to the type of additives and bases used, the formulation form of the muscle mass reduction inhibitor, etc.
添加剤及び基剤としては、デンプン、カルメロースカルシウム、軽質無水ケイ酸、ステアリン酸マグネシウム、合成ケイ酸アルミニウム、メタケイ酸アルミン酸マグネシウム、ケイ酸カルシウム、ケイ酸マグネシウム、合成ハイドロタルサイト、無水リン酸水素カルシウム、カルメロース、クロスカルメロースナトリウム、デンプングリコール酸ナトリウム、クロスポピドンが挙げられ、好ましくは、カルメロースカルシウム、軽質無水ケイ酸、ステアリン酸マグネシウム、及び合成ケイ酸アルミニウムが挙げられる。これらの添加剤及び基剤の含有量は、使用する添加剤及び基剤の種類に応じて適宜設定される。 Examples of additives and bases include starch, carmellose calcium, light anhydrous silicic acid, magnesium stearate, synthetic aluminum silicate, magnesium aluminometasilicate, calcium silicate, magnesium silicate, synthetic hydrotalcite, anhydrous calcium hydrogen phosphate, carmellose, croscarmellose sodium, sodium starch glycolate, and crospovidone, and preferred are carmellose calcium, light anhydrous silicic acid, magnesium stearate, and synthetic aluminum silicate. The content of these additives and bases is appropriately set according to the type of additive and base used.
また、本発明の四肢スリミング剤は、防風通聖散エキスの他に、必要に応じて、他の栄養成分や薬理成分を含有していてもよい。このような栄養成分や薬理成分としては、薬学的に許容されることを限度として特に制限されないが、例えば、制酸剤、健胃剤、消化剤、整腸剤、鎮痙剤、粘膜修復剤、抗炎症剤、収れん剤、鎮吐剤、鎮咳剤、去痰剤、消炎酵素剤、鎮静催眠剤、抗ヒスタミン剤、カフェイン類、強心利尿剤、抗菌剤、血管収縮剤、血管拡張剤、局所麻酔剤、生薬エキス、ビタミン類、メントール類等が挙げられる。これらの栄養成分や薬理成分は、1種単独で使用してもよく、また2種以上を組み合わせて使用してもよい。また、これらの成分の含有量については、使用する成分の種類、四肢スリミング剤の製剤形態等に応じて適宜設定される。 In addition, the limb slimming agent of the present invention may contain other nutritional components and pharmacological components as necessary, in addition to the bofu-tsusho-san extract. Such nutritional components and pharmacological components are not particularly limited as long as they are pharmacologic acceptable, and examples thereof include antacids, stomachic agents, digestive agents, intestinal regulators, antispasmodics, mucosal repair agents, anti-inflammatory agents, astringents, antiemetics, antitussives, expectorants, anti-inflammatory enzymes, sedatives, hypnotics, antihistamines, caffeine, cardiac diuretics, antibacterial agents, vasoconstrictors, vasodilators, local anesthetics, herbal extracts, vitamins, and menthols. These nutritional components and pharmacological components may be used alone or in combination of two or more. The content of these components is appropriately set depending on the type of components used, the formulation form of the limb slimming agent, and the like.
製剤形態
本発明の四肢スリミング剤の製剤形態については、経口投与が可能であることを限度として特に制限されないが、例えば、散剤、細粒剤、顆粒剤(ドライシロップを含む)、錠剤、丸剤、カプセル剤(軟カプセル剤、硬カプセル剤)等の固形状製剤;ゼリー剤等の半固形状製剤;液剤、懸濁剤、シロップ剤等の液状製剤が挙げられる。これらの製剤形態の中でも、含有成分の安定性や携帯性等の観点から、好ましくは固形状製剤が挙げられる。
The dosage form of the limb slimming agent of the present invention is not particularly limited as long as it can be administered orally, and examples thereof include solid preparations such as powders, fine granules, granules (including dry syrup), tablets, pills, capsules (soft capsules, hard capsules), etc.; semi-solid preparations such as jellies; and liquid preparations such as liquids, suspensions, syrups, etc. Among these dosage forms, solid preparations are preferred from the viewpoints of the stability and portability of the contained ingredients.
製造方法
本発明の四肢スリミング剤を前記製剤形態に調製するには、防風通聖散エキス、及び必要に応じて添加される添加剤、基剤、及び薬理成分を用いて、医薬分野で採用されている通常の製剤化手法に従って製剤化すればよい。錠剤として製剤する場合においては、好ましくは、本発明の四肢スリミング剤の製造方法は、防風通聖散エキス、又は必要に応じ添加剤、基材、他の栄養成分、及び/又は他の薬理成分と混合した防風通聖散エキス混合物を造粒する造粒工程、及び造粒物を打錠する打錠工程を含む。
Manufacturing method: To prepare the limb slimming agent of the present invention in the above-mentioned formulation form, the bofutsushosan extract and, if necessary, additives, bases, and pharmacological ingredients may be used to prepare a formulation according to a conventional formulation method employed in the pharmaceutical field. When formulated as a tablet, the manufacturing method of the limb slimming agent of the present invention preferably includes a granulation step of granulating the bofutsushosan extract or a bofutsushosan extract mixture mixed with additives, bases, other nutritional ingredients, and/or other pharmacological ingredients as necessary, and a tableting step of tableting the granulated product.
用途
本発明の四肢スリミング剤は、四肢、つまり、右上腕、左上腕、右太股、左太股、右脹脛、及び左脹脛の少なくともいずれかの周径を低減する目的で使用される。ウエストやヒップなどの体幹部分が痩せることができても、四肢は本来的に痩せにくく、これによって四肢が太い体形となりやすいところ、本発明の四肢スリミング剤によって四肢をスリミングすることで、四肢が太い体形を改善することができる。従って、本発明の四肢スリミング剤は、体形改善を目的としても使用される。
Uses The limb slimming agent of the present invention is used for the purpose of reducing the circumference of at least one of the limbs, that is, the right upper arm, the left upper arm, the right thigh, the left thigh, the right calf, and the left calf. Although the body trunk such as the waist and hips can be slimmed down, the limbs are inherently difficult to slim down, which tends to result in the limbs being thick. However, by slimming the limbs with the limb slimming agent of the present invention, the body shape of the thick limbs can be improved. Therefore, the limb slimming agent of the present invention is also used for the purpose of improving the body shape.
また、本発明の四肢スリミング剤は、四肢を効果的にスリミングすることができるため、ウエスト及び/又はヒップの周径を低減する目的でなくても用いることができる。従って、他の脂肪低減剤やダイエットによりウエストやヒップの体脂肪を低減できた一方で四肢が依然として痩せていない対象や、肥満症でなくても下肢から太り始めたことを自覚している対象等に対しても好ましく適用される。なお、本発明の四肢スリミング剤は、四肢以外の皮下脂肪や内臓脂肪に対しても優れた脂肪量低減効果を有するため、四肢に加えて、ウエスト及び/又はヒップの周径を低減する目的で用いても構わない。 In addition, since the limb slimming agent of the present invention can effectively slim the limbs, it can be used even if the purpose is not to reduce the circumference of the waist and/or hips. Therefore, it is preferably applied to subjects who have been able to reduce body fat in the waist or hips using other fat-reducing agents or dieting, but whose limbs are still not slim, and subjects who are not obese but are aware that they have started to gain weight from their lower limbs. In addition, since the limb slimming agent of the present invention has an excellent fat mass reducing effect on subcutaneous fat and visceral fat other than the limbs, it may be used for the purpose of reducing the circumference of the waist and/or hips in addition to the limbs.
さらに、本発明の四肢スリミング剤は、体脂肪を低減する一方で筋肉量の低下を抑制できるため、四肢のスリミングにおいては、筋肉量の低下を抑制しながら体脂肪を低減することができる。このため、本発明の四肢スリミング剤は、運動を行わない対象、及び食事制限を行っている対象に対しても好ましく適用される。 Furthermore, the limb slimming agent of the present invention can reduce body fat while suppressing a decrease in muscle mass, so in slimming the limbs, it is possible to reduce body fat while suppressing a decrease in muscle mass. For this reason, the limb slimming agent of the present invention is also preferably applied to subjects who do not exercise and subjects who are on a restricted diet.
用量・用法
本発明の四肢スリミング剤は経口投与によって使用される。本発明の四肢スリミング剤の用量については、投与対象者の年齢、性別、体質等に応じて適宜設定されるが、例えば、ヒト1人に対して1日当たり、防風通聖散エキスの生薬由来成分の総量が1~10g程度、好ましくは1.5~8g程度、より好ましくは1.5~6g程度となる量で、1日1~3回、好ましくは2又は3回の頻度で服用すればよい。服用タイミングについては、特に制限されず、食前、食後、又は食間のいずれであってもよいが、食前(食事の30分前)又は食間(食後2時間後)が好ましい。
Dosage and Usage: The limb slimming agent of the present invention is administered orally. The dosage of the limb slimming agent of the present invention is appropriately set according to the age, sex, constitution, etc. of the person to be administered, but for example, the total amount of the herbal medicine-derived components of the Bofu-tsushosan extract per person per day is about 1 to 10 g, preferably about 1.5 to 8 g, more preferably about 1.5 to 6 g, and may be taken 1 to 3 times, preferably 2 or 3 times, per day. The timing of administration is not particularly limited, and may be before, after, or between meals, but is preferably before (30 minutes before a meal) or between meals (2 hours after a meal).
また、本発明の四肢スリミング剤による四肢スリミング効果は、継続的な服用によって奏されるので、本発明の四肢スリミング剤は、継続的な服用(具体的には4週間以上の継続的な服用、好ましくは12週間以上の継続的な服用)を行うことが好ましい。 In addition, since the limb slimming effect of the limb slimming agent of the present invention is achieved by continuous administration, it is preferable to take the limb slimming agent of the present invention continuously (specifically, for 4 weeks or more, preferably for 12 weeks or more).
2.四肢スリミング効果を示すプレゼンテーション方法
上述のとおり、本発明の四肢スリミング剤は、四肢、つまり、右上腕、左上腕、右太股、左太股、右脹脛、及び左脹脛の少なくともいずれかの周径を低減する。従って、本発明は、更に、上述の本発明の四肢スリミング剤による四肢スリミング効果を示すプレゼンテーション方法であって、人体像またはヒト形シルエット像を用いて、上腕、左上腕、右太股、左太股、右脹脛、及び左脹脛の少なくともいずれかの太さが低減する様子を経時的に示すことを含む方法も提供する。これによって、本発明の四肢スリミング剤による優れた効果を視覚的にわかりやすく説明することができる。
2. Presentation method showing the limb slimming effect As described above, the limb slimming agent of the present invention reduces the circumference of at least one of the limbs, that is, the right upper arm, the left upper arm, the right thigh, the left thigh, the right calf, and the left calf. Therefore, the present invention also provides a presentation method for showing the limb slimming effect of the limb slimming agent of the present invention, which includes using a human body image or a human silhouette image to show the reduction in the thickness of at least one of the upper arm, the left upper arm, the right thigh, the left thigh, the right calf, and the left calf over time. This makes it possible to visually and easily explain the excellent effect of the limb slimming agent of the present invention.
具体的なプレゼンテーション方法の例を図1に示す。図1においては、本発明の四肢スリミング剤の服用前のヒト形シルエットと、服用後のヒト形シルエットとを対比できるように示しており、服用によって少なくとも四肢の太さが低減している様子を示している。つまり、図1によると、本発明の四肢スリミング剤の服用によって、上腕、左上腕、右太股、左太股、右脹脛、及び左脹脛の少なくともいずれかの太さが低減する様子を経時的に示している。なお、図1においては、四肢に加え、ウエスト及びヒップも低減している様子を示している。 A specific example of the presentation method is shown in Figure 1. In Figure 1, a human silhouette before taking the limb slimming agent of the present invention is shown for comparison with a human silhouette after taking the agent, showing how at least the thickness of the limbs is reduced by taking the agent. In other words, Figure 1 shows how the thickness of at least one of the upper arm, left upper arm, right thigh, left thigh, right calf, and left calf is reduced over time by taking the limb slimming agent of the present invention. Note that Figure 1 also shows how the waist and hips are reduced in addition to the limbs.
本発明のプレゼンテーション方法は、上述の本発明の四肢スリミング剤の効能を説明するいかなる手段においても用いることができる。そのような手段としては、当該四肢スリミング剤に関するコマーシャルメッセージ、ウェブサイト、商品パッケージ等が挙げられる。 The presentation method of the present invention can be used in any means for explaining the efficacy of the limb slimming agent of the present invention described above. Such means include commercial messages, websites, product packages, etc., relating to the limb slimming agent.
以下、本発明を実施例により具体的に説明するが、本発明はこれらの実施例に限定されるものではない。 The present invention will be described in detail below with reference to examples, but the present invention is not limited to these examples.
防風通聖散エキスの製造
表1に示す各生薬を細切して、所定の分量を混合し、細切して生薬調合物を得た。生薬調合物に、重量比で20倍量の水を加えて、約100℃で1時間撹拌しながら抽出を行った。その後、遠心分離にて抽出液を回収し、減圧濃縮した後に、スプレードライヤーを用いて乾燥させ、防風通聖散エキス末を得た。
Preparation of Bofutsushosan Extract Each herb shown in Table 1 was finely chopped, mixed in the prescribed amounts, and finely chopped to obtain a herb preparation. Twenty times the weight of water was added to the herb preparation, and extraction was carried out while stirring at about 100°C for 1 hour. The extract was then collected by centrifugation, concentrated under reduced pressure, and dried using a spray dryer to obtain Bofutsushosan extract powder.
なお、ショウキョウは1~8mm角に細切したものを使用した。また、スプレードライヤーによる乾燥は、抽出液を回転数10000rpmのアトマイザーに落下させ、150℃の熱風を供給することにより行った。 The ginger used was cut into 1-8 mm cubes. The drying using a spray dryer was performed by dropping the extract into an atomizer rotating at 10,000 rpm and supplying hot air at 150°C.
試験例1:四肢スリミング効果の評価
服用開始前において、30歳第代~40歳代(男性14名、女性9名)を対象とし、上記製造例1の組成を有する防風通聖散エキス錠を、1日当たり、防風通聖散エキスの生薬由来成分の総量が2.5gとなるよう、1日3回食前または食間に1回4錠を服用させた。なお、試験期間中において、特別な運動負荷は実施せず、食事制限も行わなかった。
Test Example 1: Evaluation of limb slimming effect Before starting to take the drug, subjects in their 30s to 40s (14 men and 9 women) were given 4 tablets of the Bofutsushosan extract tablets having the composition of Preparation Example 1 above, three times a day before or between meals, so that the total amount of the herbal medicine-derived ingredients of the Bofutsushosan extract per day was 2.5 g. During the test period, no special exercise load was performed, and no dietary restrictions were imposed.
服用前及び服用後において、身体計測(服用前、服用2週、4週、8週及び12週後)、及び身体各部サイズの計測を行った。なお、身体計測においては、体組成分析装置InBody3.2(株式会社バイオスペース)を用い、体重、BMI、体脂肪量、体脂肪率、筋肉量、筋肉率を記録した。 Before and after taking the drug, physical measurements (before taking the drug, and after 2, 4, 8, and 12 weeks of taking the drug) and measurements of various body parts were taken. For physical measurements, a body composition analyzer, InBody3.2 (Biospace Corporation), was used to record weight, BMI, body fat mass, body fat percentage, muscle mass, and muscle percentage.
身体計測結果、及び身体各部サイズ測定結果を下記表に示す。下記表における測定結果は、すべて平均値±標準偏差で示した。 The results of physical measurements and measurements of each body part are shown in the table below. All measurement results in the table below are shown as average values ± standard deviation.
表2に示すとおり、防風通聖散エキス錠の服用により、体重、BMI、体脂肪量、及び体脂肪率のいずれについても有意な減少が認められた一方で、筋肉量が減少しておらず、筋肉率の向上が認められた。また、表4に示すとおり、右上腕、左上腕、右太股、左太股、右脹脛、及び左脹脛の周径全てがおいて有意に低減しており、四肢の効果的なスリミングが確認できた。また、表2の結果において筋肉量が減少していないことに鑑みると、表4で確認された四肢のスリミングは、四肢の体脂肪が低減されたことによるものであると推認できる。また、表3に示すとおり、ウエストやヒップの周径も優位に低減されていた。このように、本来痩せにくい四肢がスリミングされたことにより、全体として体形が改善されたことが分かった。 As shown in Table 2, taking Bofutsushosan extract tablets significantly reduced body weight, BMI, body fat mass, and body fat percentage, while muscle mass did not decrease and muscle percentage increased. As shown in Table 4, the circumferences of the right upper arm, left upper arm, right thigh, left thigh, right calf, and left calf were all significantly reduced, confirming effective slimming of the limbs. In addition, considering that muscle mass did not decrease in the results of Table 2, it can be inferred that the slimming of the limbs confirmed in Table 4 is due to the reduction of body fat in the limbs. As shown in Table 3, the circumferences of the waist and hips were also significantly reduced. In this way, it was found that the overall body shape was improved by slimming the limbs, which are difficult to slim down.
Claims (5)
The limb slimming agent according to any one of claims 1 to 4, which is further used to reduce waist and/or hip circumference.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019107417A JP7554041B2 (en) | 2019-06-07 | 2019-06-07 | Limb Slimming Agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019107417A JP7554041B2 (en) | 2019-06-07 | 2019-06-07 | Limb Slimming Agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020015712A JP2020015712A (en) | 2020-01-30 |
| JP7554041B2 true JP7554041B2 (en) | 2024-09-19 |
Family
ID=69580034
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019107417A Active JP7554041B2 (en) | 2019-06-07 | 2019-06-07 | Limb Slimming Agent |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP7554041B2 (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000239138A (en) | 1998-12-16 | 2000-09-05 | Kanebo Ltd | Dropsical swelling-improving medicament and skin cosmetic preparation for reducing body weight |
| JP2008037787A (en) | 2006-08-04 | 2008-02-21 | Nisshin Pharma Inc | Anti-swelling composition |
| JP2013071913A (en) | 2011-09-28 | 2013-04-22 | Shiseido Co Ltd | Angiogenesis, forming or stabilizing agent for lymphatic vessel |
| JP2014070056A (en) | 2012-09-28 | 2014-04-21 | Oriza Yuka Kk | Fat accumulation inhibitor |
| JP2014088339A (en) | 2012-10-30 | 2014-05-15 | Toyo Shinyaku Co Ltd | Composition for swelling improvement |
-
2019
- 2019-06-07 JP JP2019107417A patent/JP7554041B2/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000239138A (en) | 1998-12-16 | 2000-09-05 | Kanebo Ltd | Dropsical swelling-improving medicament and skin cosmetic preparation for reducing body weight |
| JP2008037787A (en) | 2006-08-04 | 2008-02-21 | Nisshin Pharma Inc | Anti-swelling composition |
| JP2013071913A (en) | 2011-09-28 | 2013-04-22 | Shiseido Co Ltd | Angiogenesis, forming or stabilizing agent for lymphatic vessel |
| JP2014070056A (en) | 2012-09-28 | 2014-04-21 | Oriza Yuka Kk | Fat accumulation inhibitor |
| JP2014088339A (en) | 2012-10-30 | 2014-05-15 | Toyo Shinyaku Co Ltd | Composition for swelling improvement |
Non-Patent Citations (6)
| Title |
|---|
| 「漢方製剤 ツムラ大柴胡湯エキス顆粒(医療用)」の添付文書(第9版),2014年 |
| 「漢方製剤 ツムラ防風通聖散エキス顆粒(医療用)」の添付文書(第9版),2018年 |
| J. New Rem. & Clin.,2007年,Vol.56, No.9,pp.1624-1638 |
| J. Trad. Med.,2007年,Vol.24,pp.115-127 |
| リハビリテーション医学,2006年,Vol.43,pp.51-62 |
| 東京体育学研究,2017年,Vol.8,pp.27-32 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020015712A (en) | 2020-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7475393B2 (en) | Tablet Composition | |
| JP7821253B2 (en) | Bofutsushosan extract | |
| Nagaich et al. | Formulation and evaluation of nutraceutical tablet using herbal drugs by direct compression method | |
| JP2024092065A (en) | Lipid excretion promoter | |
| CN110960624A (en) | Anti-fatigue composition and preparation method thereof | |
| JP2025147233A (en) | Premenstrual skin irritation relief agent | |
| JP7554041B2 (en) | Limb Slimming Agent | |
| CN103735621A (en) | A traditional Chinese medicine composition capable of lowering blood fat and enhancing immunity | |
| JP7554040B2 (en) | Muscle mass loss inhibitor | |
| JP7788223B2 (en) | Fat-reducing agents | |
| CN107582866B (en) | Application method of dendrobium officinale and amlodipine in preparation of medicine for treating hypertension | |
| JP7523894B2 (en) | Fat burning accelerator | |
| JP7523895B2 (en) | Visceral fat cell decomposition agent | |
| JP7385990B2 (en) | Hypersomnia treatment | |
| JP7678663B2 (en) | Agent for improving lower limb fatigue | |
| JP7514618B2 (en) | Motivation booster | |
| CN103845467B (en) | A kind ofly be used for the treatment of medicine of the vascular hypertension of liver-yang hyperactivity of suffering from a deficiency of the kidney and preparation method thereof | |
| JP7584892B2 (en) | Muscle mass loss improvement agent | |
| Vakte et al. | Formulation and Evaluation of Nutraceutical tablets | |
| JP7719641B2 (en) | Fat excretion promoter | |
| JP7365150B2 (en) | Insomnia treatment before or during menstruation | |
| JP7376990B2 (en) | Deep body temperature improving agent | |
| JP2026008085A (en) | Blood stasis improver | |
| Suresh et al. | FORMULATION AND EVALUATION OF NUTRACEUTICAL CINNAMON TABLET BY WET GRANULATION METHOD | |
| JP2025031863A (en) | Agent for improving joint pain caused by low atmospheric pressure |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220526 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230417 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230425 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230621 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230824 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230905 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20231102 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20231215 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240319 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240517 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240820 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240906 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7554041 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |